Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors

Ignacio Melero, María de Miguel, Elena Garralda Cabanas, Guillermo de Velasco, Markus Joerger, Juan Martín-Liberal, Maria Reig, David König, Joerg Trojan, Maria-Elisabeth Goebeler, Martin Schuler, Guzman Alonso, Reinhard Dummer, Maria E. Rodríguez-Ruiz, Ramón Yarza, Giulia Pretelli, Jorge Esteban-Villarubia, Kira-Lee Koster, Paula Sabat Viltro, Marco Sanduzzi-Zamparelli, Heinz Läubli, Christine Koch, Cyrus Sayehli, Tanja Gromke, Fabricio Racca, Egle Ramelyte, Peter R. Galle, Andrea Necchi, Martin Reck, Zlatko Trajanoski, Hubert Hackl, Falk Gogolla, Jaclyn Billing, Teresa Sattmann, Jörg Wischhusen, Christine Schuberth-Wagner, Julia Akdemir, Felix S. Lichtenegger, Alexandra Auckenthaler, Marlene Fox, Kathrin Klar, Petra Fettes, Mara Liebig, Aasim Amin, Sheena Sachdeva, Frank Hermann, Eugen Leo

Open source

DOI: 10.1186/s13045-026-01818-2
Published: 2026-07-09
Container: Journal of Hematology & Oncology
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s13045-026-01818-2,
  title = {Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors},
  author = {Ignacio Melero and María de Miguel and Elena Garralda Cabanas and Guillermo de Velasco and Markus Joerger and Juan Martín-Liberal and Maria Reig and David König and Joerg Trojan and Maria-Elisabeth Goebeler and Martin Schuler and Guzman Alonso and Reinhard Dummer and Maria E. Rodríguez-Ruiz and Ramón Yarza and Giulia Pretelli and Jorge Esteban-Villarubia and Kira-Lee Koster and Paula Sabat Viltro and Marco Sanduzzi-Zamparelli and Heinz Läubli and Christine Koch and Cyrus Sayehli and Tanja Gromke and Fabricio Racca and Egle Ramelyte and Peter R. Galle and Andrea Necchi and Martin Reck and Zlatko Trajanoski and Hubert Hackl and Falk Gogolla and Jaclyn Billing and Teresa Sattmann and Jörg Wischhusen and Christine Schuberth-Wagner and Julia Akdemir and Felix S. Lichtenegger and Alexandra Auckenthaler and Marlene Fox and Kathrin Klar and Petra Fettes and Mara Liebig and Aasim Amin and Sheena Sachdeva and Frank Hermann and Eugen Leo},
  year = {2026},
  journal = {Journal of Hematology \&amp; Oncology},
  doi = {10.1186/s13045-026-01818-2},
  url = {https://doi.org/10.1186/s13045-026-01818-2}
}

RIS

TY  - JOUR
TI  - Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors
AU  - Ignacio Melero
AU  - María de Miguel
AU  - Elena Garralda Cabanas
AU  - Guillermo de Velasco
AU  - Markus Joerger
AU  - Juan Martín-Liberal
AU  - Maria Reig
AU  - David König
AU  - Joerg Trojan
AU  - Maria-Elisabeth Goebeler
AU  - Martin Schuler
AU  - Guzman Alonso
AU  - Reinhard Dummer
AU  - Maria E. Rodríguez-Ruiz
AU  - Ramón Yarza
AU  - Giulia Pretelli
AU  - Jorge Esteban-Villarubia
AU  - Kira-Lee Koster
AU  - Paula Sabat Viltro
AU  - Marco Sanduzzi-Zamparelli
AU  - Heinz Läubli
AU  - Christine Koch
AU  - Cyrus Sayehli
AU  - Tanja Gromke
AU  - Fabricio Racca
AU  - Egle Ramelyte
AU  - Peter R. Galle
AU  - Andrea Necchi
AU  - Martin Reck
AU  - Zlatko Trajanoski
AU  - Hubert Hackl
AU  - Falk Gogolla
AU  - Jaclyn Billing
AU  - Teresa Sattmann
AU  - Jörg Wischhusen
AU  - Christine Schuberth-Wagner
AU  - Julia Akdemir
AU  - Felix S. Lichtenegger
AU  - Alexandra Auckenthaler
AU  - Marlene Fox
AU  - Kathrin Klar
AU  - Petra Fettes
AU  - Mara Liebig
AU  - Aasim Amin
AU  - Sheena Sachdeva
AU  - Frank Hermann
AU  - Eugen Leo
PY  - 2026
JO  - Journal of Hematology &amp; Oncology
DO  - 10.1186/s13045-026-01818-2
UR  - https://doi.org/10.1186/s13045-026-01818-2
ER  -

APA

Melero, I., Miguel, M. D., Cabanas, E. G., Velasco, G. D., Joerger, M., Martín-Liberal, J., Reig, M., König, D., Trojan, J., Goebeler, M., Schuler, M., Alonso, G., Dummer, R., Rodríguez-Ruiz, M. E., Yarza, R., Pretelli, G., Esteban-Villarubia, J., Koster, K., Viltro, P. S., Sanduzzi-Zamparelli, M., Läubli, H., Koch, C., Sayehli, C., Gromke, T., Racca, F., Ramelyte, E., Galle, P. R., Necchi, A., Reck, M., Trajanoski, Z., Hackl, H., Gogolla, F., Billing, J., Sattmann, T., Wischhusen, J., Schuberth-Wagner, C., Akdemir, J., Lichtenegger, F. S., Auckenthaler, A., Fox, M., Klar, K., Fettes, P., Liebig, M., Amin, A., Sachdeva, S., Hermann, F., & Leo, E. (2026). Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-026-01818-2

Source records

crossref · retrieved 2026-09-26T22:42:45.436Z